Evidence map›Paper›PMID 23688050›Full record

ArticleACS nano2013

Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.

Fatih Inci, Onur Tokel, Shuqi Wang, Umut Atakan Gurkan, Savas Tasoglu, Daniel R Kuritzkes, Utkan Demirci

Abstract read
In one paragraph

Article in ACS nano, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Micro and Nanoscale Technologies for Diagnosis of Viral Infections.Small (Weinheim an der Bergstrasse, Germany) · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Current progress on COVID-19 related to biosensing technologies: New opportunity for detection and monitoring of viruses.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2021
    Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatih InciDemirci Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02139, USA.
Onur Tokel
Shuqi Wang
Umut Atakan Gurkan
Savas Tasoglu
Daniel R Kuritzkes
Utkan Demirci

Funding

Rapid Fluorescence-Based Determination of Antibiotic SusceptibilityU54EB015408 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI PARRISH, JOHN A, SCHACHTER, STEVEN · 2012 to 2022
$49.2M
Point-of-Care Rapid Blood Testing Using Microfluidic DevicesR01AI081534 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2009 to 2013
$2.1M
Novel disposable microchips for HIV-1 viral loadR01AI093282 · NIAID · STANFORD UNIVERSITY · PI DEMIRCI, UTKAN · 2012 to 2015
$1.7M
Antibody-based cell purification at resource limited setting for HIVR21AI087107 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2010 to 2011
$488k
NIAID NIH HHS R01 AI081534NIAID NIH HHS R01AI081534NIAID NIH HHS R01 AI093282NIAID NIH HHS R01AI093282NIAID NIH HHS R21 AI087107NIAID NIH HHS R21AI087107NIBIB NIH HHS U54 EB015408NIBIB NIH HHS U54EB15408
6 · The paper itself

Abstract

Infectious diseases such as HIV and hepatitis B pose an omnipresent threat to global health. Reliable, fast, accurate, and sensitive platforms that can be deployed at the point-of-care (POC) in multiple settings, such as airports and offices, for detection of infectious pathogens are essential for the management of epidemics and possible biological attacks. To the best of our knowledge, no viral load technology adaptable to the POC settings exists today due to critical technical and biological challenges. Here, we present for the first time a broadly applicable technology for quantitative, nanoplasmonic-based intact virus detection at clinically relevant concentrations. The sensing platform is based on unique nanoplasmonic properties of nanoparticles utilizing immobilized antibodies to selectively capture rapidly evolving viral subtypes. We demonstrate the capture, detection, and quantification of multiple HIV subtypes (A, B, C, D, E, G, and subtype panel) with high repeatability, sensitivity, and specificity down to 98 ± 39 copies/mL (i.e., HIV subtype D) using spiked whole blood samples and clinical discarded HIV-infected patient whole blood samples validated by the gold standard, i.e., RT-qPCR. This platform technology offers an assay time of 1 h and 10 min (1 h for capture, 10 min for detection and data analysis). The presented platform is also able to capture intact viruses at high efficiency using immuno-surface chemistry approaches directly from whole blood samples without any sample preprocessing steps such as spin-down or sorting. Evidence is presented showing the system to be accurate, repeatable, and reliable. Additionally, the presented platform technology can be broadly adapted to detect other pathogens having reasonably well-described biomarkers by adapting the surface chemistry. Thus, this broadly applicable detection platform holds great promise to be implemented at POC settings, hospitals, and primary care settings.

Indexed as

Biosensing TechniquesBloodHIVHumansNanotechnologyPolystyrenesReproducibility of ResultsViral LoadPolystyrenes

Identifiers

PMID23688050
PMCPMC3700402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.